Creo Medical Group PLC
LSE:CREO
Creo Medical Group PLC
LSE:CREO
Price:
36.5 GBX
Market Closed
Updated:
May 21, 2024
P/B
Price to Book Value
Price to Book Value
1.9
Current
2.1
Median
2.3
Industry
Lower
than median
Lower
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=1.9
Market Cap
/
128.1m
Book Value of Equity
69m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| UK |
|
Creo Medical Group PLC
LSE:CREO
|
128.1m GBP | 1.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
179.1B USD | 4.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
142B USD | 10.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.7B USD | 6.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD | 2.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
111.5B USD | 5.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.2B USD | 2.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.8B EUR | 3.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
54.2B USD | 7.6 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
51.9B USD | 23.1 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
369.4B CNY | 11.2 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
